Pulmonology
September 18, 2024
The Phase III trial of the drug Nerandomilast was the largest trial in idiopathic pulmonary fibrosis (IPF) ever conducted, ongoing at approximately 400 centers and in more than 30 countries.
Nerandomilast, an investigational oral phosphodiesterase 4B (Pde4b) inhibitor, may be a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Phase III trial was the largest trial in idiopathic pulmonary fibrosis (IPF) to date, with approximately 400 sites and more than 30 countries being conducted. Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, said: “Today’s announcement represents a new step forward in our long history of research in this disease. There are still many unmet needs for patients with idiopathic pulmonary fibrosis and we remain committed to our research efforts to develop new treatment options for one of the most common interstitial lung diseases.” IPF is one of the most common progressive fibrosing interstitial lung diseases (ILDs), affecting approximately 3 million people worldwide with symptoms such as shortness of breath, dry and persistent cough, chest discomfort, fatigue and weakness. Some of these patients may develop a progressive phenotype known as progressive pulmonary fibrosis (PPF), defined by worsening respiratory symptoms. Boehringer Ingelheim will now submit nerandomilast for approval as a new drug for the treatment of IPF to the US FDA and other health authorities around the world.
If you liked the article, stay in touch with us on our social channels by following us on:
Or stay up to date on the pharmaceutical field by subscribing to our newsletter!
YOU MAY ALSO BE INTERESTED IN
The influenza vaccine candidate generated significant immune responses against influenza A and B strains in both younger and older adults, offering efficacy…
The announcement was made to Reuters by Cris Kacita, head of the health response to the virus in the region, who confirmed that the country, the epicenter of the epidemic, has received…
In a recent article, Nathalie Moll, Director General of Efpia, analyses the opportunities that the new European Union legislature offers to strengthen the competitiveness of the…
It is one of the so-called ‘big killers’ and at the time of diagnosis up to 80% of patients have an already advanced stage of the disease. To improve medical-health care, the Ovarian board…